Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Wilson FJ"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-12 z 12
    Tytuł:
    Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review
    Autorzy:
    Rangelov BA
    Young AL
    Jacob J
    Cahn AP
    Lee S
    Wilson FJ
    Hawkes DJ
    Hurst JR
    Pokaż więcej
    Temat:
    copd
    radiology and other imaging
    emphysema
    Diseases of the respiratory system
    RC705-779
    Źródło:
    International Journal of COPD, Vol Volume 15, Pp 1751-1787 (2020)
    Opis pliku:
    electronic resource
    Relacje:
    https://www.dovepress.com/thoracic-imaging-at-exacerbation-of-chronic-obstructive-pulmonary-dise-peer-reviewed-article-COPD; https://doaj.org/toc/1178-2005
    Dostęp URL:
    https://doaj.org/article/85f49e9ca48f4bbc84494476ddb23ef4  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Clinical quantification of the integrin αvβ6 by [ F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study).
    Autorzy:
    Lukey PT; GlaxoSmithKline Research and Development, Brentford, UK. .; Target to Treatment Consulting Ltd, Stevenage BioScience Catalyst, Stevenage, SG1 2FX, UK. .
    Coello C; Invicro LLC, London, UK.
    Gunn R; Invicro LLC, London, UK.
    Parker C; GlaxoSmithKline Research and Development, Brentford, UK.
    Wilson FJ; GlaxoSmithKline Research and Development, Brentford, UK.
    Saleem A; Invicro LLC, London, UK.
    Garman N; GlaxoSmithKline Research and Development, Brentford, UK.
    Costa M; GlaxoSmithKline Research and Development, Brentford, UK.
    Kendrick S; GlaxoSmithKline Research and Development, Brentford, UK.
    Onega M; Invicro LLC, London, UK.
    Kang'ombe AR; GlaxoSmithKline Research and Development, Brentford, UK.
    Listanco A; Invicro LLC, London, UK.
    Davies J; Invicro LLC, London, UK.
    Ramada-Magalhaes J; Invicro LLC, London, UK.
    Moz S; Invicro LLC, London, UK.
    Fahy WA; GlaxoSmithKline Research and Development, Brentford, UK.
    Maher TM; NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK.; Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK.
    Jenkins G; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK.
    Passchier J; Invicro LLC, London, UK.
    Marshall RP; GlaxoSmithKline Research and Development, Brentford, UK.
    Pokaż więcej
    Źródło:
    European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Apr; Vol. 47 (4), pp. 967-979. Date of Electronic Publication: 2019 Dec 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Integrins*
    Positron Emission Tomography Computed Tomography*
    Antigens, Neoplasm ; Humans ; Lung/diagnostic imaging ; Positron-Emission Tomography
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Preclinical evaluation of [ F]FB-A20FMDV2 as a selective marker for measuring α V β 6 integrin occupancy using positron emission tomography in rodent lung.
    Autorzy:
    Onega M; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Parker CA; GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Hertfordshire, SG1 2NY, UK.
    Coello C; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Rizzo G; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Keat N; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Ramada-Magalhaes J; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Moz S; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Tang SP; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Plisson C; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Wells L; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Ashworth S; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Slack RJ; GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Hertfordshire, SG1 2NY, UK.
    Vitulli G; GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Hertfordshire, SG1 2NY, UK.
    Wilson FJ; GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Hertfordshire, SG1 2NY, UK.
    Gunn R; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
    Lukey PT; GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Hertfordshire, SG1 2NY, UK.
    Passchier J; Imanova Ltd trading as Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. .
    Pokaż więcej
    Źródło:
    European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Apr; Vol. 47 (4), pp. 958-966. Date of Electronic Publication: 2020 Jan 03.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Integrins*/metabolism
    Rodentia*/metabolism
    Animals ; Antigens, Neoplasm ; Integrin beta Chains ; Lung/diagnostic imaging ; Positron-Emission Tomography ; Rats ; Rats, Sprague-Dawley ; Tissue Distribution
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor.
    Autorzy:
    Maher TM; Royal Brompton Hospital, London, UK.; National Heart and Lung Institute, Imperial College London, London, UK.
    Simpson JK; GlaxoSmithKline Research and Development, Stevenage, UK.
    Porter JC; University College London Hospital, London, UK.
    Wilson FJ; GlaxoSmithKline Research and Development, Stevenage, UK.
    Chan R; GlaxoSmithKline Research and Development, Stevenage, UK.
    Eames R; GlaxoSmithKline Research and Development, Stevenage, UK.
    Cui Y; GlaxoSmithKline Research and Development, Stevenage, UK.
    Siederer S; GlaxoSmithKline Research and Development, Stevenage, UK.
    Parry S; GlaxoSmithKline Research and Development, Stevenage, UK.
    Kenny J; GlaxoSmithKline Research and Development, Stevenage, UK.
    Slack RJ; GlaxoSmithKline Research and Development, Stevenage, UK.
    Sahota J; University College London Hospital, London, UK.
    Paul L; Royal Brompton Hospital, London, UK.
    Saunders P; Royal Brompton Hospital, London, UK.; National Heart and Lung Institute, Imperial College London, London, UK.
    Molyneaux PL; Royal Brompton Hospital, London, UK.; National Heart and Lung Institute, Imperial College London, London, UK.
    Lukey PT; GlaxoSmithKline Research and Development, Stevenage, UK.
    Rizzo G; Invicro, A Konica Minolta Company, London, UK.
    Searle GE; Invicro, A Konica Minolta Company, London, UK.
    Marshall RP; GlaxoSmithKline Research and Development, Stevenage, UK.
    Saleem A; Invicro, A Konica Minolta Company, London, UK.
    Kang'ombe AR; GlaxoSmithKline Research and Development, Stevenage, UK.
    Fairman D; GlaxoSmithKline Research and Development, Stevenage, UK.
    Fahy WA; GlaxoSmithKline Research and Development, Stevenage, UK.
    Vahdati-Bolouri M; GlaxoSmithKline Research and Development, Stevenage, UK. .
    Pokaż więcej
    Źródło:
    Respiratory research [Respir Res] 2020 Mar 26; Vol. 21 (1), pp. 75. Date of Electronic Publication: 2020 Mar 26.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
    MeSH Terms:
    Butyrates/*therapeutic use
    Idiopathic Pulmonary Fibrosis/*drug therapy
    Integrins/*antagonists & inhibitors
    Naphthyridines/*therapeutic use
    Pyrazoles/*therapeutic use
    Pyrrolidines/*therapeutic use
    Tidal Volume/*drug effects
    Administration, Inhalation ; Aged ; Antigens, Neoplasm ; Bayes Theorem ; Butyrates/administration & dosage ; Butyrates/pharmacokinetics ; Double-Blind Method ; Endpoint Determination ; Female ; Humans ; Idiopathic Pulmonary Fibrosis/diagnostic imaging ; Male ; Naphthyridines/administration & dosage ; Naphthyridines/pharmacokinetics ; Nebulizers and Vaporizers ; Positron-Emission Tomography ; Pyrazoles/administration & dosage ; Pyrazoles/pharmacokinetics ; Pyrrolidines/administration & dosage ; Pyrrolidines/pharmacokinetics ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Reproducibility of compartmental modelling of F-FDG PET/CT to evaluate lung inflammation.
    Autorzy:
    Vass LD; Experimental Medicine and Immunotherapeutics, Department of Medicine, Addenbrookes Hospital, Cambridge, UK. .
    Lee S; Amallis Consulting LTD, London, UK.
    Wilson FJ; GSK R &D, Brentford, UK.
    Fisk M; Experimental Medicine and Immunotherapeutics, Department of Medicine, Addenbrookes Hospital, Cambridge, UK.; Cambridge University Hospitals NHS Trust, Cambridge, UK.
    Cheriyan J; Experimental Medicine and Immunotherapeutics, Department of Medicine, Addenbrookes Hospital, Cambridge, UK.; GSK R &D, Brentford, UK.; Cambridge University Hospitals NHS Trust, Cambridge, UK.
    Wilkinson I; Experimental Medicine and Immunotherapeutics, Department of Medicine, Addenbrookes Hospital, Cambridge, UK.; Cambridge University Hospitals NHS Trust, Cambridge, UK.
    Pokaż więcej
    Źródło:
    EJNMMI physics [EJNMMI Phys] 2019 Dec 16; Vol. 6 (1), pp. 26. Date of Electronic Publication: 2019 Dec 16.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Quantitative analysis of dynamic F-FDG PET/CT for measurement of lung inflammation.
    Autorzy:
    Coello C; Imanova Ltd., Centre for Imaging Sciences, Hammersmith Hospital, London, UK. .; Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK. .
    Fisk M; Experimental Medicine and Immunotherapeutics (EMIT) Division, Department of Medicine, University of Cambridge, Cambridge, UK.
    Mohan D; NIHR Respiratory Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, UK.; GSK R&D, King of Prussia, PA, USA.
    Wilson FJ; GSK R&D, Stevenage, UK.
    Brown AP; Imanova Ltd., Centre for Imaging Sciences, Hammersmith Hospital, London, UK.
    Polkey MI; NIHR Respiratory Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, UK.
    Wilkinson I; Experimental Medicine and Immunotherapeutics (EMIT) Division, Department of Medicine, University of Cambridge, Cambridge, UK.; Cambridge Clinical Trials Unit, Addenbrooke's Hospital, Cambridge, UK.
    Tal-Singer R; GSK R&D, King of Prussia, PA, USA.
    Murphy PS; GSK R&D, Stevenage, UK.
    Cheriyan J; Experimental Medicine and Immunotherapeutics (EMIT) Division, Department of Medicine, University of Cambridge, Cambridge, UK.; GSK R&D, Cambridge, UK.; Cambridge Clinical Trials Unit, Addenbrooke's Hospital, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, University of Cambridge, Cambridge, UK.
    Gunn RN; Imanova Ltd., Centre for Imaging Sciences, Hammersmith Hospital, London, UK.; Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK.; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
    Pokaż więcej
    Źródło:
    EJNMMI research [EJNMMI Res] 2017 Dec; Vol. 7 (1), pp. 47. Date of Electronic Publication: 2017 May 25.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-12 z 12

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies